Recipharm and CTC unite for early-stage trials

Contract developer Recipharm and CTC Clinical Trial Consultants are joining forces to offer combined Phase I services, pooling their capabilities in manufacturing and trial conduction.

Evotec pockets a payment in its Boehringer partnership

German contractor Evotec has notched another milestone in its years-long arrangement with Boehringer Ingelheim, netting €1 million ($1.4 million) after moving a respiratory compound into preclinical study.

ClinicalRM teams up with an Ohio network for clinical trials

CRO ClinicalRM has signed a deal with the Ohio Clinical Trials Collaborative to join forces in a co-marketing arrangement, looking to expand its role in the state's drug and device development scene.

Bristol-Myers enlists Duke's CRO to help it share trial data

Bristol-Myers Squibb has tapped Duke University's in-house CRO to pitch in on clinical trial transparency, asking the organization's researchers to independently review requests for shared data.

Parexel expects to hit the $2B mark in fiscal 2015

Parexel figures it can rake in more than $2 billion in revenue in the next fiscal year, banking on a solid book-to-bill ratio and increasing global demand to deliver an all-time high.

Covance is creating an OkCupid for molecules

As last week's BIO conference well illustrated, biotech companies go to great lengths to flaunt their assets in front of potential partners from Big Pharma. Global CRO Covance is developing a system it believes can make that process more efficient: an online platform that allows drug developers to securely list their up-for-license molecules for would-be collaborators.

Teva settles with Catalent, Perrigo in inhaler patent suit

Catalent and Perrigo will be able to sell generic versions of Teva's ProAir HFA inhaler starting in late 2016, resolving a patent dispute between the two parties.

Parexel rolls out new eClinical tech to speed up study start-up

Parexel International has reformatted its clinical trial management software, streamlining its services with an update the company believes can help its clients start studies faster.

Simbec buys its way into late-stage R&D with Orion deal

Welsh CRO Simbec Research is expanding beyond its focus on early-phase studies, buying up Orion Clinical Services in a move the company says will make it a full-service organization.

Japanese CRO taps BBK for a U.S. joint venture

Japan's CROèe, a patient-recruitment-focused contractor, has deepened its ties with partner BBK, launching a joint venture in the U.S. to provide a gateway into the country's growing market for drug development.

Quintiles partners up to flex its commercial muscles

Quintiles believes in better drug sales through data analytics, signing a deal with a marketing-optimization company to pool resources and figure out how to better reach physicians on behalf of its commercialization clients.

BioClinica dives into adaptive trials with latest buy

Just three months after wrapping its latest merger, BioClinica has made another acquisition, snapping up Blueprint Clinical to expand its capabilities in the growing field of risk-based management.

Accelera signs up for pioneering CAR-T research

Preclinical CRO Accelera has teamed up with French biotech Cellectis to investigate a cancer therapy in the promising CAR-T class, treatments that use a patient's own T cells to attack tumors....

After a year of dealmaking, PRA settles in with a new identity

A year removed from the $1.3 billion deal that made it a top-5 CRO, PRA has integrated its various acquisitions and is rebranding itself as a sprawling global drug development resourcer.

Korean pharma booster recruits Novotech to boost local R&D

Novotech, which bills itself as Australia's largest CRO, has signed a deal with a South Korean outfit to help bolster the country's status among global drug development locales.

Quintiles signs an expansive deal to chart effects of physical therapy

Quintiles, the world's largest CRO, is lending its Big Data heft to the American Physical Therapy Association, agreeing to help create a registry of patient outcomes data to inform future treatment.

Karyopharm taps CRO Veristat for cancer R&D

Biotech Karyopharm Therapeutics has signed a deal with Veristat, recruiting the CRO to serve as a preferred partner as it develops a pipeline of first-in-class oncology treatments.

InVentiv, Oncobiologics kick off their biosimilar alliance, target Humira

CRO inVentiv Health and biotech partner Oncobiologics have a plot to cash in on the burgeoning market for knockoffs of biotech drugs, and the two have begun development on a biosimilar of the blockbuster Humira.

Parexel eyes a $150M share buyback

Parexel International has approved a stock repurchase program of up to $150 million, and the company plans to use its existing cash and credit to buy up its own shares and boost investor value. 

CROs unite to kick-start a biotech's pipeline

Four pharma service providers, led by MPI Research, have joined forces to form KPI Therapeutics, a new biotech designed to develop promising drug candidates and speed their way to market.